Category |
Gastroenterology & Hepatology |
Manuscript Type |
Clinical Trials Study |
Article Title |
Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
PN Rao, Abraham Koshy, Jacob Philip, Narayanan Premaletha, Joy Varghese, Krishnasamy Narayanasamy, Samir Mohindra, Nitin Vikas Pai, Manoj Kumar Agarwal, Ashoknanda Konar and Hasmukh B Vora |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Virchow Biotech Private Limited, Hyderabad, India |
|
|
Corresponding Author |
PN Rao, MD, DM, Department of Gastroenterology, Asian Institute of Gastroenterology, 6-3-661, Somajiguda, Hyderabad 500082, India. pnrcraig@gmail.com |
Key Words |
Hepatitis C virus; Genotype; Peginterferon alfa-2b; Ribavirin; Treatment |
Core Tip |
In a multicenter study, the safety and efficacy of pegylated interferon alfa-2b, indigenously developed in India, plus ribavirin was evaluated on 100 hepatitis C virus (HCV) patients with genotypes 1, 2, 3, and 4. Eighty-two patients completed the study. Most patients had mild-to-moderate adverse events, although 11 serious adverse events were reported in 9 patients. However, only 4 of these were related to study medication. The percentage of serologic response (rapid virologic response, early virologic response, and sustained virologic response rates) of patients was similar to that reported in published studies. In conclusion, peginterferon alfa-2b, developed in India, is a safe and cost-effective drug in the treatment of Indian patients with HCV infection. |
Publish Date |
2014-07-25 16:43 |
Citation |
Rao PN, Koshy A, Philip J, Premaletha N, Varghese J, Narayanasamy K, Mohindra S, Pai NV, Agarwal MK, Konar A, Vora HB. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014; 6(7): 520-526 |
URL |
http://www.wjgnet.com/1948-5182/full/v6/i7/520.htm |
DOI |
http://dx.doi.org/10.4254/wjh.v6.i7.520 |